CORONA Remedies Ltd (CORONA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Corona Remedies was originally incorporated as ‘CORONA Remedies Private Limited’, a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, the company was converted into a public limited company pursuant to a special resolution passed by its Shareholders on October 24, 2024, and consequently, the name of the company was changed to ‘CORONA Remedies Limited’. A fresh certificate of incorporation, upon conversion of the company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.

The company is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Its diversified product portfolio comprises brands that cater to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory. 

The company are also focused on executing strategic brand acquisitions and establishing in-licensing arrangements to address therapy gaps in its portfolio and to establish complementary capabilities, such as backward integration, marketing arrangements, and diversified product offerings. This enables it to broaden its therapeutic presence and enhance its market position across key areas. Its customers primarily comprise pharmacies, specialty treatment facilities, other outpatient clients, physicians and hospitals. It primarily offers its products in India. It offers products across the following therapeutic areas: (i) women’s health; (ii) cardio-diabeto, (iii) pain management; (iv) urology; and (v) others/multispecialty pharmaceuticals (comprising VMN, gastrointestinal and respiratory).

Business area of the company

The company is primarily engaged in the business of manufacturing, trading and marketing of pharmaceutical products. The company also has an associate which is involved in similar line of business. Its diversified product portfolio comprises brands that cater to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory. 

Products of the company

Women’s health products

• C-HOP
• COR-9
• Dydrohope

Cardio-diabeto

• Rosuless
• Cortel
• Obimet
• Sitabite

Pain management

• Myoril
• Myoril Maxx
• Myoril Plus
• GB-29

Urology

• Dosin
• Alkashot

Others products

• Ulpan
• Respicure
• Vitneurin

Awards, accreditations and recognition

• 2014: Awarded ‘Emerging Company of the Year’ at the AWACS Awards for market excellence.
• 2014: Its brand ‘XOCLAVE’ was awarded the ‘Brand of the Year’ for the Drug Price Control Order category at the AWACS Awards for market excellence.
• 2015: Awarded the CIMS Healthcare Excellence Award.
• 2016: Its brand ‘FUR-XT’ was awarded the ‘New Introduction of the Year’ award at the AWACS Awards for market excellence.
• 2018: Its brand ‘B-29’ was recognised as one of ‘India’s 50 Most Admired Brands’ title by White Page International.
• 2018: Awarded the ‘Best Pharma Distribution Strategy’ award at the Global Logistics Excellence Awards.
• 2019: Awarded the ‘Dr. Shamsheer Shaikh Company of the Year’ award at the 6th AWACS Awards.
• 2022: Implemented SAP S/4 HANA (an enterprise resource planning software suite).
• 2022: Achieved the Edge Advanced Certificate for exemplifying achievement in energy savings, water savings and less embodied energy in materials by Green Business Certifications Inc.
• 2023: Received a Good Manufacturing Practice certificate from the State Unitary Enterprise, Center of Good Practices for compliance with the requirements of O’zDSt 2766:2018.
• 2024: Recognised by the Asia Book of Records for screening the maximum patients for peripheral neuropathy using a biothesiometer in a single week.
• 2025: Received 2024 DET Hurun Award for outstanding contribution to India’s manufacturing economy, from Hurun India Manufacturing 400.

History and milestones

• 2004: Launch of first division, later named as ‘Pioneer’ division in 2010.
• 2005: Launch of division (multispeciality): Xemx.
• 2007: Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh.
• 2008: Launch of division (gynaecology): Aarush.
• 2013: Launch of division (cardioloy): Wellness.
• 2016: Purchased the trademarks ‘Stelbid’ and ‘Vitneurin’ from Glaxo Group Limited.
• 2016: Purchased the trademarks ‘Dilo DX’ and ‘Dilo-BM’ from GlaxoSmithKline Pharmaceuticals Limited.
• 2018: Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis.
• 2018: Acquired the trademarks ‘Obimet’, ‘Obimet-GX’, ‘Obimet SR’, ‘Obimet-V’ ‘Triobimet’ and ‘Thyrocab’ (within India) from Abbott India Limited.
• 2020: Entered into a strategic alliance with La Chandra Pharmalab Private Limited.
• 2021: Commencement of production at the manufacturing plant at Ahmedabad, Gujarat.
• 2022: Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris.
• 2023: Launch of division (urology): Blaze.
• 2023: Purchased the trademark ‘Myoril’ (in India) from Sanofi Healthcare India Private Limited.
• 2023: Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat.